上海交通大学学报（医学版）

上海交通大学学报（医学版） ›› 2018, Vol. 38 ›› Issue (7): 819-.doi: 10.3969/j.issn.1674-8115.2018.07.020

• 综述 • 上一篇    下一篇

受体酪氨酸激酶AXL在肿瘤耐药中的作用研究进展

张义朋 1，黄华艳 1，仰昳婕 1，徐懂懂 1，张可人 1,2，朱亮 1, 2, 3   

  1. 1. 上海交通大学基础医学院，上海200025；2. 上海交通大学基础医学院药理学与化学生物学系，上海200025；3. 上海交通大学医学院转化医学协同创新中心，上海 200025
  • 出版日期:2018-07-28 发布日期:2018-07-30
  • 作者简介:张义朋（1997—），男，本科生；电子信箱：15821905156@163.com。
  • 基金资助:
    国家自然科学基金（81573018）；上海交通大学医学院第11期大学生创新训练计划项目（1117002）

Role of receptor tyrosine kinase AXL in tumor drug resistance

ZHANG Yi-peng1, HUANG Hua-yan1, YANG Yi-jie1, XU Dong-dong1, ZHANG Ke-ren1, 2, ZHU Liang1, 2, 3   

  1. 1. Shanghai Jiao Tong University College of Basic Medical Sciences, Shanghai 200025, China; 2. Department of Pharmacology and Chemical Biology, Shanghai Jiao Tong University College of Basic Medical Sciences, Shanghai 200025, China; 3. Cooperative Innovation Center of Translational Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
  • Online:2018-07-28 Published:2018-07-30
  • Supported by:
    National Natural Science Foundation of China,81573018; The 11th Undergraduate Training Program for Innovation of Shanghai Jiao Tong University School of Medicine, 1117002

PDF (PC)

1524

摘要： AXL属于受体酪氨酸激酶中的TAM（TYRO3-AXL-MER）家族，在非小细胞肺癌、乳腺癌、卵巢癌等多种癌症中高表达，并介导上皮间质转化的发生，在肿瘤耐药中起重要作用；AXL还可以通过调节信号通路以及影响肿瘤微环境等来介导靶向治疗耐药的产生。临床上，AXL对于肿瘤患者的预后评价具有重要意义，以AXL为靶点的治疗有望成为一项治疗癌症的新策略。目前已有AXL多靶点小分子抑制剂被批准上市，还有多种特异性更高的抑制剂正处于临床或临床前研究阶段。该文着重介绍了AXL介导肿瘤耐药的机制，并总结不同AXL抑制剂的研究概况，从而为以AXL为靶点的抗肿瘤研究和治疗提供新思路。

关键词: AXL, 受体酪氨酸激酶, 肿瘤, 耐药, 上皮间质转化, 小分子抑制剂, 预后

Abstract:

AXL is a member of TAM (TYRO3-AXL-MER) family of receptor tyrosine kinases, which is overexpressed in many cancers, including non-small cell lung cancer, breast cancer and ovarian cancer. It can mediate the occurrence of epithelial-mesenchymal transition, and plays an important role in tumor drug resistance. In addition, AXL can also mediate the occurrence of targeted agents resistanceregulating the signaling pathway and influencing tumor microenviroment. As a result, AXL is an attractive candidate not only as a prognostic indicator in malignancy but also as a target for anti-cancer therapy. Several multi-target small molecule inhibitors against AXL have been approved, and varieties of inhibitors with higher specificity are in clinical or preclinical studies. This article focused on the role of AXL in tumor drug resistance and summarized the research profiles of different small molecule inhibitors against AXL to provide new ideas for anti-tumor research and therapy.

Key words: AXL, receptor tyrosine kinase, tumor, drug resistance, epithelial-mesenchymal transition, small molecule inhibitor, prognosis

中图分类号: